To be a worldwide biopharmaceutical business delivering great medicines to patients through
innovative science and excellence in development and exploitation.
Mission: to push the boundaries of science to deliver life changing medicines
AstraZeneca strategy is targeted on innovation with 3 strategic priorities:
Achieve scientific leadership delivering the complete potential of our distinctive combination of discovery and development strengths in tiny molecule and biologics, immunotherapies and macromolecule engineering. This includes progressing our phase II clinical trial pipeline (which has the potential to double our phase III clinical trial pipeline by 2016), and launching a gradual flow of specialty care product, equalization our historic strength in medical care. Return to growth focusing our industrial experience on key wellness franchises and high potential marketplaces. Be a good place to figure building a culture that's science and patient-focused, agile and high-performing, that retains and attracts potential consumer. This includes simplifying our organization and up production whereas making aspirated, cooperative work surroundings.
Global marketing of new medicine Ability to deliver the potential of existing and future merchandise through the facility and reach of a combined world sales and selling resource Widespread category coverage in key medical care areas, like vessel and disease, owing to complementary nature of merchandise Major medical care presence, significantly in canal, vessel and metabolic process drugs Leading position in a very variety of specialist/hospital markets, together with medicine and anesthesia
Research and development of AstraZeneca AstraZeneca is now the second largest investor in research and development in the pharmaceutical industry world-wide.
AstraZeneca has been able to dramatically increase the scale of the research and development, providing more manpower, improved, shared technology and a larger number of laboratories.
Globally, our R&D focus is on six key therapeutic areas where we believe our skills and experience can make the most difference: cancer, infection, cardiovascular diseases and diabetes, gastrointestinal, neuroscience and respiratory.
Partnering, collaborations and open innovation remain key to pushing boundaries of science We are driving science through collaborations, more than 90 partnerships in the last three years. To deliver through the next generation of medicines, work in alliance management to achieve the best science and medication thats happening elsewhere. The quality of transformation across our business underpins our confidence in AstraZeneca longer term prospect Accessing through an open innovation website , Advancing research together.